Prognostic and clinicopathological significance of microRNA-200 family in lung cancer : a meta-analysis

Xiong Peng,Yuxuan Song,W. Bai,S. Xie,Daya Luo,Wei Zhang

2019-01-01

Abstract:Background/Aim: In recent years, the relationship between miR-200 expression and prognosis in lung cancer patients has been studied extensively. The miR-200 family plays a vital role in occurrence, development, metastasis, and drug resistance of lung cancer. Increasing evidence has shown that the miR-200 family is highly expressed in lung cancer and associated with poor prognosis. However, results have been inconclusive. Therefore, the aim of this study was to assess the association between miR-200 family expression and the clinicopathological and prognostic significance in patients with lung cancer via conducting a meta-analysis. Methods: A total of 9 different publications were searched from PubMed, Web of Science, Embase, and Cochrane library databases. Summary hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random-effects/fixed-effects models. Results: A total of nine articles, consisting of 812 patients, were included in this meta-analysis. Pooling all eligible studies, this study found a shorter overall survival in patients with high expression of the miR-200 family (HR = 2.29, 95% CI: 1.10-4.73). Furthermore, subgroup analysis, based on area, demonstrated that a significant association was found between higher expression of the miR-200 family and poor overall survival (HR = 4.70, 95% CI: 1.5913.89) in the European population. However, there was no significant association between high expression of the miR-200 family and poor PFS (HR = 1.40, 95% CI: 0.21-9.25). In addition, this study failed to observe a correlation of increased miR-200 family expression with clinicopathological parameters, including age, sex, histology, tumor node metastasis (TNM) stage, lymph node metastasis, and tumor differentiation. Conclusion: High expression of the miR-200 family is significantly associated with poor clinical outcomes, particularly decreasing overall survival for European populations. Future studies should be performed to confirm the clinical utility of the miR-200 family in lung cancer.